Immunoinformatics Approach to Design Novel Subunit Vaccine against the Epstein-Barr Virus
Abu Tayab Moin, Rajesh B. Patil, Tahani Tabassum, Yusha Araf, Md. Asad Ullah, Hafsa Jarin Snigdha, Tawfiq Alam, Safwan Araf Alvey, Bashudev Rudra, Sohana Akter Mina, Yasmin Akter, Jingbo Zhai, Chunfu Zheng
Abstract
Epstein-Barr virus (EBV) vaccines have been developing for over 30 years, but polyphyletic and therapeutic vaccines have failed to get licensed. Our vaccine surpasses the limitations of many such vaccines and remains very promising, which is crucial because the infection rate is higher than most viral infections, affecting a whopping 90% of the adult population. One of the major identifications covers a holistic analysis of populations worldwide, giving us crucial information about its effectiveness for everyone's unique immunological system. We targeted three glycoproteins that enhance the virulence of the virus to design an epitope-based polyvalent vaccine against two different strains of EBV, type 1 and 2. Our methodology in this study is nonconventional yet swift to show effective results while designing vaccines.